Business & Finance

Watson certifies substantial compliance with FTC second request

Published in Biotech Law Weekly, November 17th, 2006

Watson Pharmaceuticals, Inc., (WPI) announced that it has certified to the Federal Trade Commission (FTC) that it believes it is in substantial compliance with the FTC's May 1, 2006 request for additional information (also known as a second request).

The FTC issued the second request in connection with its review of Watson's pending acquisition of Andrx Corp. (ADRX) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). Andrx had previously submitted its certificate of substantial compliance.

Based on Watson's submission of its certificate of substantial compliance, Watson believes the waiting period imposed under...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2006-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry